The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: A multicenter, prospective, open-label, observational study in Korea

Annals of Hematology

Volumn 93, Issue 1, 2014, Pages 33-42

  Kim, Jin Seok ^a   Cheong, June Won ^a   Kim, Yeo Kyeoung ^b   Park, Jinny ^c   Mun, Yeung Chul ^d   Kang, Hye Jin ^e   Yi, Hyeon Gyu ^f   Lee, Je Hwan ^g   Kim, Yang Soo ^h   Ryoo, Hun Mo ⁱ   Kim, Sung Hyun ^j   Kim, Ho Young ^k   Kim, Jin Young ^l   Lee, Dong Gun ^m   Kim, Hoon Gu ⁿ   Kim, Hawk ^o   Joo, Young Don ^p   Min, Yoo Hong ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Chonnam National University   (South Korea)

^c Gachon University College of Medicine   (South Korea)

^d Ewha Womans University School of Medicine   (South Korea)

^e Korea Cancer Center Hospital   (South Korea)

^f Inha University School of Medicine   (South Korea)

^g University of Ulsan   (South Korea)

^h Kosin University College of Medicine   (South Korea)

ⁱ Catholic University of Daegu   (South Korea)

^j Dong A University College of Medicine   (South Korea)

^k Hallym University   (South Korea)

^l Keimyung University   (South Korea)

^m The Catholic University of Korea   (South Korea)

ⁿ Gyeongsang National University   (South Korea)

^o Ulsan University College of Medicine   (South Korea)

^p Inje University College of Medicine   (South Korea)

more..

Author keywords

Empirical antifungal therapy; Hematological malignancy; Hydroxy itraconazole; itraconazole; Therapeutic drug monitoring

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; HYDROXYITRACONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CANCER PATIENT; CARDIOVASCULAR DISEASE; COMORBIDITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; KOREA; LIVER TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; YOUNG ADULT;

EID: 84891844859     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1826-x     Document Type: Article

References (32)

1. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91(8):1068-1075 (Pubitemid 44208634)
2. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A (2010) Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95(4):644-650
3. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M (2007) Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 25(34):5471-5489 (Pubitemid 350232225)
4. Vardakas KZ, Michalopoulos A, Falagas ME (2005) Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 131(1):22-28 (Pubitemid 43899704)
5. Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T, Marklein G, Schmidt-Wolf IG (1999) Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 42(7-8):443-451 (Pubitemid 29470385)
6. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813-1821
7. Ruhnke M, Bohme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, Enzensberger R, Hebart H, Heussel CP, Horger M, Hof H, Karthaus M, Kruger W, Maschmeyer G, Penack O, Ritter J, Schwartz S (2012) Diagnosis of invasive fungal infections in hematology and oncology - guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 23(4):823-833
8. Wingard JR (2004) Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 39(Suppl 1):S38-S43 (Pubitemid 38971474)
9. Martino R, Viscoli C (2006) Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 132(2):138-154
10. Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, Choi JH (2011) Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 26(2):220-252
11. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427-431
12. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of A (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327-360 (Pubitemid 351265310)
13. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P, Gachot B, Heinz WJ, Lass-Florl C, Ribaud P, Thiebaut A, Cordonnier C (2011) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 46(5):709-718
14. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135(6):412-422 (Pubitemid 32845866)
15. Schuler U, Bammer S, Aulitzky WE, Binder C, Bohme A, Egerer G, Sandherr M, Schwerdtfeger R, Silling G, Wandt H, Glasmacher A, Ehninger G (2007) Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 30(4):185-191 (Pubitemid 46482161)
16. Ohta K, Nishiki Kosaka S, Nakao Y, Kumura T, Hagihara K, Sakamoto E, Okamoto S, Hirose A, Aoyama Y, Yamamura R, Hayashi Y, Umemoto Y, Terada Y, Takeoka Y, Nakane T, Koh H, Hino M (2009) Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan. Int J Hematol 89(5):649-655
17. Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Min WS, Shin WS (2006) Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever. Korean J Intern Med 21(3):165-172 (Pubitemid 44823258)
18. Goodwin ML, Drew RH (2008) Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 61(1):17-25
19. Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW (2009) Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 49(6):928-930
20. Shimoeda S, Nakagawa S, Kobayashi H, Yamato S, Kawano K, Ohta S (2010) Clinical significance of measuring the blood concentration of itraconazole oral solution in the field of hematology. Biol Pharm Bull 33(11):1861-1866
21. Lee DG, Chae H, Yim DS, Park SH, Choi SM, Kim S, Choi JH, Yoo JH, Shin WS (2009) Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. J Clin Pharm Ther 34(3):337-344
22. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33(8):e83-e90
23. Mino Y, Naito T, Watanabe T, Yamada T, Yagi T, Yamada H, Kawakami J (2013) Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. Clin Chim Acta 16(415):128-132
24. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340(10):764-771 (Pubitemid 29114295)
25. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346(4):225-234 (Pubitemid 34438861)
26. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351(14):1391-1402 (Pubitemid 39288165)
27. Prentice AG, Glasmacher A (2005) Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 56(Suppl 1):i17-i22 (Pubitemid 41236086)
28. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31-41
29. Maertens JA, Klont R, Masson C, Theunissen K, Meersseman W, Lagrou K, Heinen C, Crepin B, Van Eldere J, Tabouret M, Donnelly JP, Verweij PE (2007) Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 44(10):1329-1336 (Pubitemid 46729195)
30. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Bossuyt PM, Vandenbroucke-Grauls CM (2008) Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev (4):CD007394
31. Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, Miller PJ, Ribaud P, Schlamm HT, Solano C, Cook G, Group IS (2011) Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 155(3):318-327
32. Mossad SB (2012) Posaconazole is not superior to itraconazole for fungal prophylaxis in allogeneic blood and marrow transplantation. Bone Marrow Transplant 47(10):1379